Merck & Company – Consensus Indicates Potential 28.3% Upside

Broker Ratings

Merck & Company with ticker code (MRK) now have 20 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 107 and 80 calculating the average target price we see 92.42. Given that the stocks previous close was at 72.04 this now indicates there is a potential upside of 28.3%. The 50 day MA is 75.5 and the 200 day MA is 74.97. The company has a market cap of $184,917m. Company Website: http://www.merck.com

Merck & Co. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women’s health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics to evaluate LNS8801. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations, as well as with IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of a specific version of Mallya device. Merck & Co. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

You might also enjoy reading  Merck & Company - Consensus Indicates Potential 5.0% Upside
Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index